Cohance Lifesciences Executive and Leadership Team

Yann D'Herve, the Chief Executive Officer at Cohance Lifesciences, directs the overarching corporate strategy and long-term growth initiatives for the organization. D'Herve manages the expansion of global CDMO capabilities, specifically targeting the advancement of Antibody Drug Conjugates and complex small molecule pipelines. By aligning internal research resources with the evolving needs of pharmaceutical innovators, the Chief Executive Officer ensures the company maintains a competitive edge in the global market. D'Herve oversees the integration of clinical analytical services to streamline the path from discovery to commercial scale. This leadership role involves constant collaboration with the Board to refine operational goals and enhance service delivery. Through the implementation of rigorous quality standards, Yann D'Herve drives the organization toward sustainable development and operational excellence, ultimately securing the company's position as a premier partner for complex molecule manufacturing across international markets.

Umang Vohra, the Executive Chairman & Global Chief Executive Officer at Cohance Lifesciences, governs the strategic vision and international market presence of the firm. Vohra architects the high-level framework for global operations, ensuring that the company effectively supports pharmaceutical clients through every stage of the drug development lifecycle. The Executive Chairman & Global Chief Executive Officer monitors the alignment of regional business units with the broader corporate mission of delivering high-quality, scalable manufacturing solutions. Umang Vohra facilitates critical partnerships with global innovators, focusing on the rapid deployment of Nucleic Acid Chemistry and API development services. By optimizing the organizational structure, Vohra enhances the efficiency of cross-functional teams. This leadership position requires constant oversight of market trends and regulatory landscapes to maintain the company's reputation for excellence. Ultimately, Vohra secures the long-term financial health and strategic trajectory of the entire enterprise.

Gunjan Singh, the Chief Executive Officer, Api Plus (Api & Formulations) at Cohance Lifesciences, directs the specialized development and manufacturing of active pharmaceutical ingredients and complex formulations. Singh manages the technical teams responsible for scaling production processes to meet commercial requirements for global pharmaceutical partners. The Chief Executive Officer, Api Plus (Api & Formulations) oversees the integration of advanced chemistry techniques to ensure high-purity output and consistent quality across all product lines. Gunjan Singh drives the operational efficiency of the API division, focusing on reducing time-to-market for critical drug candidates. This role involves close coordination with clinical analytical departments to ensure seamless transitions from development to full-scale manufacturing. By prioritizing innovation in formulation science, Singh strengthens the company's portfolio. Ultimately, the Chief Executive Officer, Api Plus (Api & Formulations) ensures that the organization remains a leader in the competitive landscape of small molecule manufacturing.

Sunil Uttarwar, the Chief Operating Officer, Technology Operations at Cohance Lifesciences, manages the technical infrastructure and manufacturing systems that underpin the company's CDMO services. Uttarwar architects the deployment of advanced manufacturing technologies, ensuring that all facilities operate at peak efficiency and adhere to stringent global quality standards. The Chief Operating Officer, Technology Operations oversees the implementation of innovative processes for Antibody Drug Conjugates and other complex molecules. Sunil Uttarwar drives the modernization of production lines to support the increasing demand for high-complexity pharmaceutical manufacturing. This leadership role involves coordinating with engineering and quality assurance teams to optimize workflows and minimize operational risks. By focusing on technological scalability, Uttarwar ensures that the company can handle diverse client requirements from early-stage development to large-scale commercial production. Through these efforts, the Chief Operating Officer, Technology Operations maintains the technical superiority of the organization's manufacturing capabilities.

Ravinath Shetty, the Chief Operating Officer, Platform at Cohance Lifesciences, directs the development and maintenance of the core service platforms that support the company's diverse CDMO offerings. Shetty manages the operational frameworks for Nucleic Acid Chemistry and clinical analytical services, ensuring that these platforms remain agile and responsive to client needs. The Chief Operating Officer, Platform oversees the integration of cross-functional resources to streamline project delivery and enhance service consistency. Ravinath Shetty drives the optimization of internal processes, focusing on resource allocation and capacity management to support global market expansion. This role involves constant interaction with technical leads to ensure that the platform capabilities evolve alongside emerging pharmaceutical trends. By standardizing operational procedures, Shetty improves the reliability of the company's service delivery model. Ultimately, the Chief Operating Officer, Platform secures the operational foundation necessary for the company to provide integrated, high-value solutions to pharmaceutical innovators worldwide.